Muscle dysfunction in the long coronavirus disease 2019 syndrome : Pathogenesis and clinical approach
© 2022 John Wiley & Sons Ltd..
In long coronavirus disease 2019 (long COVID-19), involvement of the musculoskeletal system is characterised by the persistence or appearance of symptoms such as fatigue, muscle weakness, myalgia, and decline in physical and functional performance, even at 4 weeks after the onset of acute symptoms of COVID-19. Muscle injury biomarkers are altered during the acute phase of the disease. The cellular damage and hyperinflammatory state induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may contribute to the persistence of symptoms, hypoxaemia, mitochondrial damage, and dysregulation of the renin-angiotensin system. In addition, the occurrence of cerebrovascular diseases, involvement of the peripheral nervous system, and harmful effects of hospitalisation, such as the use of drugs, immobility, and weakness acquired in the intensive care unit, all aggravate muscle damage. Here, we review the multifactorial mechanisms of muscle tissue injury, aggravating conditions, and associated sequelae in long COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Reviews in medical virology - 32(2022), 6 vom: 06. Nov., Seite e2355 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Silva, Camilla Costa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 11.11.2022 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/rmv.2355 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339458895 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339458895 | ||
| 003 | DE-627 | ||
| 005 | 20231226002937.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rmv.2355 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339458895 | ||
| 035 | |a (NLM)35416359 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Silva, Camilla Costa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Muscle dysfunction in the long coronavirus disease 2019 syndrome |b Pathogenesis and clinical approach |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.11.2022 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons Ltd. | ||
| 520 | |a In long coronavirus disease 2019 (long COVID-19), involvement of the musculoskeletal system is characterised by the persistence or appearance of symptoms such as fatigue, muscle weakness, myalgia, and decline in physical and functional performance, even at 4 weeks after the onset of acute symptoms of COVID-19. Muscle injury biomarkers are altered during the acute phase of the disease. The cellular damage and hyperinflammatory state induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may contribute to the persistence of symptoms, hypoxaemia, mitochondrial damage, and dysregulation of the renin-angiotensin system. In addition, the occurrence of cerebrovascular diseases, involvement of the peripheral nervous system, and harmful effects of hospitalisation, such as the use of drugs, immobility, and weakness acquired in the intensive care unit, all aggravate muscle damage. Here, we review the multifactorial mechanisms of muscle tissue injury, aggravating conditions, and associated sequelae in long COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a long COVID-19 | |
| 650 | 4 | |a muscle | |
| 650 | 4 | |a muscle dysfunction | |
| 650 | 4 | |a muscle sequelae | |
| 700 | 1 | |a Bichara, Clea Nazaré Carneiro |e verfasserin |4 aut | |
| 700 | 1 | |a Carneiro, Francisca Regina Oliveira |e verfasserin |4 aut | |
| 700 | 1 | |a Palacios, Vera Regina da Cunha Menezes |e verfasserin |4 aut | |
| 700 | 1 | |a Berg, Ana Virgínia Soares Van den |e verfasserin |4 aut | |
| 700 | 1 | |a Quaresma, Juarez Antônio Simões |e verfasserin |4 aut | |
| 700 | 1 | |a Magno Falcão, Luiz Fábio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Reviews in medical virology |d 1996 |g 32(2022), 6 vom: 06. Nov., Seite e2355 |w (DE-627)NLM090684788 |x 1099-1654 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2022 |g number:6 |g day:06 |g month:11 |g pages:e2355 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rmv.2355 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2022 |e 6 |b 06 |c 11 |h e2355 | ||